| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 05/18/2011 | EP2322615A1 Use of unmethylated CpG oligonucleotides for the treatment of allergy |
| 05/18/2011 | EP2322610A1 Anti-human clcp1 antibody and use thereof |
| 05/18/2011 | EP2322608A1 Transfection agent |
| 05/18/2011 | EP2322560A1 Anti-mesothelin antibodies |
| 05/18/2011 | EP2322559A2 Neoplasm specific antibodies and uses thereof |
| 05/18/2011 | EP2322557A2 Compositions and methods for treating proliferative disorders |
| 05/18/2011 | EP2322551A2 Compositions comprising Anti-IGF-1R Antibodies and Methods for their Production |
| 05/18/2011 | EP2322550A1 Compositions comprising anti-IGF-1R Antibodies and Methods for obtaining said Antibodies |
| 05/18/2011 | EP2322549A1 Connective tissue growth factor antibodies |
| 05/18/2011 | EP2322537A1 Tubulin inhibitors |
| 05/18/2011 | EP2322528A1 Stemonamide synthesis intermediate and pharmaceutical composition for prevention and/or treatment of cancer |
| 05/18/2011 | EP2322527A1 Triazole derivatives |
| 05/18/2011 | EP2322523A1 Pyridopyrimidinone Inhibitors of PI3Kalpha |
| 05/18/2011 | EP2322517A1 Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (MTC) |
| 05/18/2011 | EP2322501A1 4-dedimethylamino tetracycline compounds |
| 05/18/2011 | EP2322500A1 Fluoro-labeled homo-glutamate derivatives and precursors thereof |
| 05/18/2011 | EP2322229A2 Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF) |
| 05/18/2011 | EP2322228A1 T cell receptor fusions and conjugates and methods of use thereof |
| 05/18/2011 | EP2322224A1 Potentiator of activity of anti-cancer agent and use thereof, and biomarker for prediction of prognosis in cancer patient and use thereof |
| 05/18/2011 | EP2322221A1 Pharmaceutical composition for treatment and prevention of cancer |
| 05/18/2011 | EP2322218A1 Methods of modulating CD200 receptors |
| 05/18/2011 | EP2322212A1 Compositon of antigen and glycolipid adjuvant for sublingual administration |
| 05/18/2011 | EP2322210A1 Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide |
| 05/18/2011 | EP2322209A2 Tumor specific oligosaccharide epitopes and use thereof |
| 05/18/2011 | EP2322204A1 Pharmaceutical compositions comprising an LRP1 receptor agonist for the treatment of cancer and HIV |
| 05/18/2011 | EP2322173A1 Cationic bacteriochlorophyll derivatives and uses thereof |
| 05/18/2011 | EP2322165A1 Apo2 ligand/TRAIL formulations |
| 05/18/2011 | EP2322160A1 Methods of inducing terminal differentiation |
| 05/18/2011 | EP2322154A2 Methods for detecting and clearing cross beta structure comprising proteins with crossbeta structure binding compounds. |
| 05/18/2011 | EP2321411A1 Melk epitope peptides and vaccines containing the same |
| 05/18/2011 | EP2321328A1 Mimetics of sulfated oligosaccharides |
| 05/18/2011 | EP2321325A1 Antitumoral macrolides |
| 05/18/2011 | EP2321323A1 Dimeric derivatives of artemisinin and application in anti-cancer therapy |
| 05/18/2011 | EP2321320A1 Novel compounds and their uses in diagnosis |
| 05/18/2011 | EP2321318A1 Pyrazolopyridine kinase inhibitors |
| 05/18/2011 | EP2321299A2 Pyridons as pdk1 inhibitors |
| 05/18/2011 | EP2321298A2 Aurora kinase modulators and methods of use |
| 05/18/2011 | EP2321295A2 4-(pyridin-4-yl)-1h-[1,3,5]triazin-2-one derivatives as gsk3-beta inhibitors for the treatment of neurodegenerative diseases |
| 05/18/2011 | EP2321283A1 2, 6-diamino-pyrimidin- 5-yl-carboxamides as syk or jak kinases inhibitors |
| 05/18/2011 | EP2321271A1 Organosulfur compounds, a method of making organosulfur compounds and their use for inhibiting the growth of tumour cells |
| 05/18/2011 | EP2321264A2 Deacetylase inhibitors and uses thereof |
| 05/18/2011 | EP2321012A1 Organoarsenic compounds and methods for the treatment of cancer |
| 05/18/2011 | EP2320947A2 Alpha-galactosyl ceramide analogs and their use as immunotherapies, adjuvants, and intiviral, antibacterial, and anticancer agents |
| 05/18/2011 | EP2320941A2 Composition and methods for eliciting an immune response |
| 05/18/2011 | EP2320935A1 Soluble igf receptors as anti-angiogenic agents |
| 05/18/2011 | EP2320932A2 Methods of predicting cancer lethality using replikin counts |
| 05/18/2011 | EP2320921A1 Compositions comprising tea tree oil and methods for the prevention and treatment of cancer |
| 05/18/2011 | EP2320913A1 Nucleic acid aptamers |
| 05/18/2011 | EP2320903A1 THERAPEUTIC COMBINATION COMPRISING A CDKs INHIBITOR AND AN ANTINEOPLASTIC AGENT |
| 05/18/2011 | EP2320900A1 Use of opioids or opioid mimetics for the treatment of resistant cancer patients |
| 05/18/2011 | EP2320896A2 Vinpocetine and eburnamonine derivatives for promoting bone growth |
| 05/18/2011 | EP2320895A2 Cdk modulators |
| 05/18/2011 | EP2320894A1 Chemoprevention of head and neck squamous cell carcinomas |
| 05/18/2011 | EP2320887A1 Pharmaceutical compositions comprising lignans and their derivatives for treating hyperplastic diseases |
| 05/18/2011 | EP2320881A1 Cannabinoids in combination with non -cannabinoid chemotherapeutic agents (e.g. serm or alkylating agents) |
| 05/18/2011 | EP2320879A2 Pharmaceutical composition comprising jasmonates |
| 05/18/2011 | EP2320874A1 Solid pharmaceutical composition comprising exemestane |
| 05/18/2011 | EP2320729A1 Glycoside compounds and pharmaceutical compositions thereof |
| 05/18/2011 | EP2158194B1 Derivatives of 7-alkynyl-1,8-naphthyridones, preparation method thereof and use of same in therapeutics |
| 05/18/2011 | EP2089433B1 Therapy targeting cathepsin s |
| 05/18/2011 | EP2089024B1 Combination of iap inhibitors and flt3 inhibitors |
| 05/18/2011 | EP1966245B1 Anti-cd19 antibodies with reduced immunogenicity |
| 05/18/2011 | EP1943232B1 Squaric acid derivatives as inhibitors of histone deacetylase |
| 05/18/2011 | EP1919920B1 Pentacyclic kinase inhibitors |
| 05/18/2011 | EP1833850B9 Framework residue substituted humanized col-1 antibodies and their use |
| 05/18/2011 | EP1796688B1 Pancreatic cancer treatment using na+/k+ atpase inhibitors |
| 05/18/2011 | EP1781622B1 Integrin alpha-v beta-3 antagonists for use in imaging and therapy |
| 05/18/2011 | EP1698618B1 Benzamide derivative |
| 05/18/2011 | EP1478764B1 Humanized collagen antibodies and related methods |
| 05/18/2011 | EP1379499B1 New diaminedithiol derivatives and radiorhenium or radiotechnetium complex thereof; a liver cancer-treating composition comprising the radiorhenium complex and lipiodol; and a kit for preparation of the liver cancer-treating composition |
| 05/18/2011 | EP1268096B9 Extrusion die |
| 05/18/2011 | CN1982329B Biologically active peptide comprising tyrosyl-seryl-valine (YSV) and use thereof |
| 05/18/2011 | CN1962684B Triterpene saponin compound, its preparing method and use thereof |
| 05/18/2011 | CN1962665B Extraction method of antineoplastic composition bhang flavone A from bhang |
| 05/18/2011 | CN1810970B CpG-containing single-stranded deoxynucleotide, its vaccine composition and their application |
| 05/18/2011 | CN1727340B Temozolomide 8-carboxylic ester, and combination |
| 05/18/2011 | CN1665554B Compounds and method for preparing surfaces in a haemocompatible manner |
| 05/18/2011 | CN1527704B Compositions and method of administering tubulin binding agents for the treatment of ocular diseases |
| 05/18/2011 | CN102066412A Treatment of diseases and conditions mediated by eicosanoids |
| 05/18/2011 | CN102066398A Antioxidant inflammation modulators: C-17 homologated oleanolic acid derivatives |
| 05/18/2011 | CN102066397A Compounds including an anti-inflammatory pharmacore and methods of use |
| 05/18/2011 | CN102066386A Boronate ester compounds and pharmaceutical compositions thereof |
| 05/18/2011 | CN102066378A 3-(3-pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazine derivatives as MET kinase inhibitors |
| 05/18/2011 | CN102066371A Aryl-quinolyl compounds and their use |
| 05/18/2011 | CN102066367A Thiazolyl piperdine derivatives |
| 05/18/2011 | CN102066365A Thiophene or thiazole derivatives and their use as PI3K inhibitors |
| 05/18/2011 | CN102066353A Disubstituted phthalazine Hedgehog pathway antagonists |
| 05/18/2011 | CN102066340A 2, 6-diamino-pyrimidin- 5-yl-carboxamides as SRK or JAK kinases inhibitors |
| 05/18/2011 | CN102066339A 2, 6-diamino- pyrimidin- 5-yl-carboxamides as SYK or JAK kinases inhibitors |
| 05/18/2011 | CN102066338A Inhibitors of protein kinases |
| 05/18/2011 | CN102065906A Methods for radiolabelling macromolecules |
| 05/18/2011 | CN102065886A Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions |
| 05/18/2011 | CN102065873A Abrogating proinflammatory cytokine production during oncolytic reovirus therapy |
| 05/18/2011 | CN102065868A Compositions for inducing immune responses specific to Globo h and SSEA3 and uses thereof in cancer treatment |
| 05/18/2011 | CN102065866A Combinations comprising methotrexate and dhodh inhibitors |
| 05/18/2011 | CN102065865A Multiple myeloma treatments |
| 05/18/2011 | CN102061322A Method for preparing polysaccharide, flavone and dietary fiber of peanut hulls in united manner |
| 05/18/2011 | CN102061310A Construction and application of human FHL1C eukaryotic expression vector |
| 05/18/2011 | CN102061288A Molecular antigen arrays using a virus like particle derived from the AP205 coat protein |
| 05/18/2011 | CN102061285A Application method for medicament based on NAD<+> and NADH |